Brief: Rhythm Pharmaceuticals Q2 Net Income USD -46.632 Million Vs. IBES Estimate USD -41.3 Million

Rhythm Pharmaceuticals

05/08/2025 12:00

Overview

Rhythm Pharmaceuticals Q2 2025 product revenue rises 67% yr/yr to $48.5 mln

However, net loss widens to $46.6 mln

Co raised $189.2 mln in upsized public offering, strengthening financial position

Outlook

Rhythm expects Q3 2025 regulatory submissions for setmelanotide

Company anticipates $285 mln to $315 mln in 2025 Non-GAAP Operating Expenses

Rhythm plans to disclose Phase 2 Prader-Willi trial results in H2 2025

Company expects cash reserves to fund operations for at least 24 months

Result Drivers

IMCIVREE SALES - Revenue growth driven by increased sales of IMCIVREE for Bardet-Biedl syndrome treatment

CLINICAL TRIAL SUCCESS - Positive Phase 2 and Phase 3 trial results for bivamelagon and setmelanotide in acquired hypothalamic obesity

EXPENSES - R&D and SG&A expenses rose sharply, affecting net income

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
$48.50 mln
Q2 Net Income
Miss
-$46.63 mln
-$41.30 mln (11 Analysts)
Q2 Operating Income
-$45.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Rhythm Pharmaceuticals Inc is $103.50, about 12.8% above its August 4 closing price of $90.24

Press Release: ID:nGNX9MC9MQ

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)